Search Results - Therapeutics

HOME SEARCH RSS
50 Results Sort By:
Development of an Endothelial Nitric Oxide Synthase Mutant Resistant to Inhibition by Oxidative Stress for the Treatment of Endothelial Dysfunction
Current State of the Art:A major complication of vascular disease is endothelial dysfunction caused by oxidative stress to the vasculature.  Treatment options include surgery, implantation of stints, medications and lifestyle changes.  Currently there are no gene therapy treatments available for endothelial dysfunction.  Available chemical and phar...
Published: 8/14/2019   |   Inventor(s): Stephen Black, Ruslan Rafikov
Keywords(s):  
Category(s): Therapeutics
Sulfoglucuronosyl paragloboside regulation in inflammation: use of siRNA and/or antisense oligonucleotide as anti-inflammatories
TECH ID 2011-028 Title: Methods and Compositions for Maintaining Blood-Brain Barrier IntegrityCurrent State of the Art: The BBB tightly regulates access to the brain that prevents large molecule therapy transport. Certain infections and disorders would benefit from allowing controlled access of therapeutics across the BBB including but not limited ...
Published: 8/14/2019   |   Inventor(s): Robert Yu, Somsankar Dasgupta
Keywords(s):  
Category(s): Therapeutics
A Delivery Method for a Gene Correction Reagent in Mammalian Cells Including Hematopoietic and Other Stem Cells
Current State of the Art:Gene therapy involves the use of introducing healthy genes into a patient whose own genes are defective.  In theory, the genes introduced will combine with the patient’s DNA in targeted cells to trigger production of healthy cells.  Gene therapy has become a viable medical treatment option for certain diseases.  Many curren...
Published: 8/14/2019   |   Inventor(s): Steffen Meiler, William Dynan
Keywords(s):  
Category(s): Therapeutics
Sphingolipid Metabolite Mimetics Synthesis and Use in Cancer Therapy
Current State of the Art:Lipids are fatty substances found in every cell in our bodies. Sphingolipids are a particular family of lipids which are bioeffectors that mediate various cellular processes. They were discovered in that late 19th century by German biochemist Johann Thudichum who is said to have named them after the sphinx because they w...
Published: 8/13/2019   |   Inventor(s): Kebin Liu, Feiyan Liu, Ping Wu, Zhizhen Huang
Keywords(s):  
Category(s): Therapeutics
Autologous or Allogeneic Mesenchymal Stem Cell Therapy for Premature Ovarian Failure and other forms of ovarian-based female infertility
Premature ovarian failure (POP) is defined as hypergonadotropic ovarian failure occurring prior to age 40. AU researchers used human bone marrow mesenchymal stem cells to reverse infertility in a chemotherapy induced ovarian failure mouse model. The cells were delivered by direct intra-ovarian injection. The treatment were successful with all treat...
Published: 8/13/2019   |   Inventor(s): Ayman Al-Hendy
Keywords(s):  
Category(s): Therapeutics
Manipulation of the p53 pathway as a novel target for cancer immunotherapy
AU researchers have identified a novel population of immunogenic dendritic cells that arise from rapid transdifferentiation of immature myeloid-derived suppressor ceils (MOSCs) in tumors. We have discovered that this DC trans-differentiation step is driven by p53 expressed by the host (not the tumor). Mice with a deletion of p53 in host cells lose ...
Published: 8/13/2019   |   Inventor(s): David Munn
Keywords(s):  
Category(s): Therapeutics
Fc receptor targeted and virus-like particle (VLP) based tripartite chimeric vaccine technology
TECH ID 2012-025 Title: Tripartitie Polypeptide Vaccine Vector Current State of the Art: Although traditionally viewed as an anti-infectious preventive measure, vaccine use has expanded to treating non-infectious diseases including cancer. Provenge (Dendreon) is currently the only FDA approved therapeutic vaccine at approximately $95,000 per treatm...
Published: 8/13/2019   |   Inventor(s): Yukai He, David Munn, Yuan Hong
Keywords(s):  
Category(s): Therapeutics
Verticillin A, Therapeutic Agent for Colon Cancer and Leukemia
TitleVerticillin A, Therapeutic Agent for Colon Cancer and LeukemiaCurrent State of the ArtHistone specific methyltransferases (HMTase) are over expressed in certain colon cancer and leukemia cells. Inhibitors of HMTase prevent methylations of histone residues and inhibit the development and progression of the cancer cells.Problem with the Current ...
Published: 8/13/2019   |   Inventor(s): Kebin Liu, Feiyan Liu, Ping Wu
Keywords(s):  
Category(s): Therapeutics
Novel Hsp90 Inhibitors for Breast Cancer Treatment
TitleNovel Hsp90 Inhibitors for Breast Cancer TreatmentPresent State of the ArtHsp90 (heat shock proteins) are popular cancer drug targets due to their anti-apoptotic activities. Several classes of Hsp90 inhibitors are in clinical trial.Problem of the Present ArtHsp90 inhibitors are often successful in diminishing or deactivating the Hsp90 in the c...
Published: 8/13/2019   |   Inventor(s): Ahmed Chadli, Abdessamad Debbab, Peter Proksch
Keywords(s):  
Category(s): Therapeutics
GPR81 Agonists Based Therapeutics
TitleGPR81 Agonists Based TherapeuticsCurrent State of the ArtMucosal immunity plays an important role for the prevention and cure of different pathogenic diseases.These urogenital, intestinal, and respiratory diseases are often caused by viruses, bacteria, fungi, or parasites than can diffuse through the mucosal immunity system. Different drugs ha...
Published: 8/13/2019   |   Inventor(s): Vadivel Ganapathy, Nagendra Singh, Ashish Gurav
Keywords(s):  
Category(s): Therapeutics
1 2 3 4 5 
© 2019. All Rights Reserved. Powered by Inteum